Review

ROLE OF HOMOEOPATHY IN THE MANAGEMENT OF DYSLIPIDEMIA: A COMPREHENSIVE REVIEW

Pankaj Soni[1], Alpana Choudhary[2]

[1]M.D. Scholar [Department of Homoeopathic Repertory and Case Taking], State National Homoeopathic Medical College and Hospital, Lucknow.

[2]M.D. [HOM.], HOD [Department of Homoeopathic Repertory and Case Taking] , State National Homoeopathic Medical College and Hospital, Lucknow.

ABSTRACT

Background: To review the clinical epidemiology, pathophysiology, operational evaluation, and conventional management of dyslipidemia while systematically analyzing the complementary therapeutic scope, repertorial rubrics, and recent evidence-based clinical trial developments of individualized homoeopathy. **Methodology:** A comprehensive analysis of peer-reviewed biomedical literature, international cardiovascular guidelines, foundational homoeopathic texts, and authoritative modern repertories [Synthesis, Murphy, Complete, and Boger Boenninghausen] was performed alongside a critical synthesis of randomized controlled exploratory trials and observational studies. **Key Findings:** Dyslipidemia is a major, modifiable driver of vascular atherosclerosis and coronary artery disease. While conventional paradigms favor statin therapies, barriers like statin-associated muscle symptoms [SAMS] and financial burdens remain prominent challenges. Homoeopathy provides an individualized framework using specific deep-acting and organotrophic remedies mapped to targeted rubric categories across prominent repertories. Recent trials provide quantifiable statistical validation, highlighting a significant reduction in serum LDL-C [7.03 ± 3.3 mg/dL] using individualized interventions over placebo controls, alongside measurable biological improvements via specialized Mother Tinctures like Guatteria gaumeri. **Conclusion:** Individualized homoeopathy, coupled with heart-healthy dietary and lifestyle modifications, provides a holistic framework for managing lipid abnormalities. Recent controlled exploratory data marks clear progress, though robust, larger-scale multi-centric randomized configurations remain vital to solidify universal translation.

Keywords: Dyslipidemia, Homoeopathy, Hypercholesterolemia, Cardiovascular Disease, Lipid Metabolism.

INTRODUCTION

Dyslipidemia is a common metabolic disorder characterized by abnormal levels of lipids and lipoproteins in the blood, including elevated Total Cholesterol [TC], Low-Density Lipoprotein [LDL], Very-Low-Density Lipoprotein [VLDL], Triglycerides [TG], and/or reduced High-Density Lipoprotein [HDL]. 1 It is a major risk factor for atherosclerosis, coronary artery disease, stroke, and peripheral vascular disorders. 2 As one of the leading modifiable cardiovascular risk factors, dyslipidemia contributes significantly to the global burden of cardiovascular disease. 3 In India, the ICMR–INDIAB study reported that more than 70% of adults have at least one lipid abnormality, largely attributed to sedentary lifestyles, unhealthy dietary habits, obesity, and metabolic syndrome. 4 Since dyslipidemia often remains asymptomatic until complications develop, early diagnosis and effective management are essential. 5 While effective, long-term use may be associated with adverse effects and increased economic burden.6 Homoeopathy, founded by Dr. Samuel Hahnemann, is a holistic system of medicine based on the principle of "Similia Similibus Curentur."7 It aims to restore health through individualized treatment by considering the physical, mental, emotional, and constitutional characteristics of the patient.8 Remedies such as Chionanthus virginica, Fel Tauri, Bryonia alba, Podophyllum, Kali bichromicum, and Robinia pseudo acacia are traditionally used for their action on hepatic and digestive functions. 9

The Repertory serves as a valuable tool for remedy selection, with the Repertorium Homoeopathicum Syntheticum [Synthesis Repertory] being one of the most comprehensive and widely utilized repertories in contemporary homoeopathy. 10,11 Despite extensive clinical use, scientific evidence demonstrating objective improvements in lipid parameters through homoeopathic treatment remains limited.[12,13] Therefore, further well-designed studies employing standardized biochemical outcomes are needed to evaluate the effectiveness of homoeopathy in dyslipidemia management. 14

DYSLIPIDEMIA

Dyslipidemia is a metabolic disorder characterized by abnormal concentrations of blood lipids, includ-

www.njmrys.com
eISSN: 2395-2911
Date of Received: 17-11-2025
Date of Acceptance: 07-12-2025
Date of Publication: 01-01-2026

Correspondence: Dr. Pankaj Soni, State National Homoeopathic Medical College and Hospital, Lucknow.
Email:sonipankaj949@gmail.com

ing elevated Total Cholesterol [TC], Low-Density Lipoprotein Cholesterol [LDL-C], Very-Low-Density Lipoprotein [VLDL], Triglycerides [TG], and/or reduced High-Density Lipoprotein Cholesterol [HDL-C]. Lipids are essential for cellular integrity, hormone synthesis, bile acid production, and energy storage. However, persistent lipid imbalance promotes endothelial dysfunction, oxidative stress, inflammation, and atherosclerotic plaque formation, thereby increasing the risk of coronary artery disease, myocardial infarction, stroke, and peripheral vascular disease. 15

The development of dyslipidemia is influenced by genetic susceptibility, dietary habits, obesity, insulin resistance, smoking, alcohol consumption, and physical inactivity. Elevated LDL and triglyceride-rich lipoproteins accelerate atherogenesis, while reduced HDL impairs reverse cholesterol transport, further increasing cardiovascular risk. 16

EPIDEMIOLOGY

Dyslipidemia is one of the leading contributors to cardiovascular disease globally, with prevalence estimates ranging from 20% to 80% depending on population characteristics and diagnostic criteria. Despite its high prevalence, awareness, treatment, and control rates remain inadequate, particularly in low- and middle-income countries. In the United States, approximately one-third of adults have elevated LDL cholesterol, yet many remain untreated or fail to achieve recommended lipid targets. 17,18

The burden of dyslipidemia extends beyond cardiovascular morbidity and mortality, imposing significant economic costs on healthcare systems worldwide. Epidemiological evidence demonstrates that reducing LDL cholesterol significantly lowers the risk of major vascular events, coronary mortality, and stroke. Gender- and age-related differences also exist, with increasing prevalence observed among postmenopausal women and children affected by obesity and sedentary lifestyles. These trends highlight the importance of population-based prevention, screening, and long-term management strategies. 19

ETIOLOGY

Dyslipidemia results from a combination of genetic and acquired factors and is broadly classified into primary and secondary forms. 17

Primary Dyslipidemia

Primary dyslipidemia arises from inherited genetic abnormalities affecting lipid synthesis, transport, or clearance. Major disorders include familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, and familial dysbetalipoproteinemia. These conditions are associated with mutations involving LDL receptors, apolipoproteins, or enzymes responsible for lipid metabolism, leading to elevated plasma cholesterol and triglyceride levels and an increased risk of premature cardiovascular disease. 17

Secondary Dyslipidemia

Secondary dyslipidemia develops due to lifestyle factors or underlying medical conditions. Common causes include obesity, diabetes mellitus, hypothyroidism, chronic kidney disease, liver disease, excessive alcohol consumption, smoking, physical inactivity, and the use of medications such as corticosteroids, oral contraceptives, beta-blockers, and antiretroviral agents. These factors alter lipid metabolism through increased lipoprotein production, impaired lipid clearance, or reduced HDL levels, thereby contributing to abnormal lipid profiles. 17

PATHOPHYSIOLOGY

Dyslipidemia contributes to cardiovascular and metabolic disorders through mechanisms involving inflammation, oxidative stress, endothelial dysfunction, and altered lipid metabolism.

Inflammation: Elevated LDL and triglyceride-rich lipoproteins accumulate within arterial walls, initiating inflammatory responses that promote atherosclerosis. Activation of macrophages, T cells, cytokines, chemokines, and adhesion molecules [ICAM-1 and VCAM-1] facilitates vascular inflammation and endothelial injury. Dyslipidemia also impairs endothelial progenitor cells, reducing vascular repair capacity. 20

Oxidative Stress: Retained LDL undergoes oxidation to form oxidized LDL [oxLDL], which enhances foam cell formation, activates inflammatory pathways, and accelerates plaque development. Reduced antioxidant activity and impaired HDL function further increase oxidative damage. 17,20

Cardiovascular Effects: Dyslipidemia promotes atherosclerosis, endothelial dysfunction, reduced nitric oxide availability, and abnormal vascular tone, thereby increasing the risk of coronary artery disease, stroke, peripheral arterial disease, heart failure, and other cardiovascular complications. 17

Metabolic Dysfunction: Abnormal lipid metabolism adversely affects the liver, pancreas, adipose tissue, and skeletal muscle, contributing to insulin resistance, obesity, diabetes mellitus, and metabolic syndrome. 17

SIGNS AND SYMPTOMS OF DYSLIPIDEMIA

Dyslipidemia is often asymptomatic and is frequently detected through routine lipid screening. Clinical manifestations usually appear after the development of vascular or metabolic complications. Family history and associated cardiovascular risk factors should always be assessed. Common signs and complications include:

Severe Hypertriglyceridemia [>1000 mg/dL]: Increased risk of acute pancreatitis.

Eruptive Xanthomas: Yellow-red papules over extensor surfaces and buttocks due to elevated triglycerides.

Tendon Xanthomas: Cholesterol deposits over tendons, commonly associated with familial hypercholesterolemia.

Xanthelasma: Yellowish plaques around the eyelids.

Xanthomatosis: Painless cholesterol-rich nodules in soft tissues.

Corneal Arcus: Grey-white corneal ring, particularly significant when occurring at a young age.

Angina Pectoris: Chest pain resulting from coronary artery disease.

Transient Ischemic Attacks and Stroke: Neurological manifestations caused by atherosclerotic cerebrovascular disease. 17

DISCUSSION [CRITICAL ANALYSIS AND LIMITATIONS OF CURRENT LITERATURE

While individual homoeopathic case series and historical records report successful management of hyperlipidemia, a critical evaluation reveals a significant gap between clinical observation and rigorous scientific validation. The primary methodological limitation in current homoeopathic research is the historical reliance on retrospective studies, unblinded clinical trials, or single-arm case series. Without matching placebo control arms, it is difficult to isolate the true therapeutic effect of a homoeopathic remedy from confounding variables like concurrent dietary and lifestyle shifts.

However, recent high-quality evidence from multicentric designs—such as the randomized controlled exploratory trial by Varanasi et al. [2025]—presents a solid benchmark by demonstrating statistically significant reductions in serum LDL-C [7.03 ± 3.3 mg/dL] using rigorous intention-to-treat analysis. Similarly, localized trial data for specific organotrophic options like Guatteria gaumeri shows measurable biochemical improvements, reducing triglycerides by 17.70% and increasing cardioprotective HDL by 14.09%, whereas comparative trials favor individualized prescribing over standard single mother tinctures such as Allium sativum.

Limitations of Current Literature: Despite these positive developments, several significant limitations within the current body of literature must be noted. Most available studies feature small sample sizes and brief follow-up windows [typically 2 to 6 months]. While these durations are sufficient to measure fluctuations in surrogate laboratory blood lipid values, they fail to track hard macrovascular outcomes, such as major adverse cardiovascular events [MACE], carotid intima-media thickness [CIMT] changes, or long-term mortality reduction. Furthermore, individualized prescribing introduces high therapeutic heterogeneity, making standard replication difficult. To definitively demonstrate clinical validity, future trial models must expand on large-scale multi-centric double-blind randomized frameworks [RCTs] with standardized biochemical outcome measurements to ensure reliable cross-disciplinary translation.

CONCLUSIONS

Dyslipidemia is a common metabolic disorder and a major modifiable risk factor for cardiovascular diseases. Its rising prevalence is largely attributed to unhealthy dietary habits, sedentary lifestyles, obesity, and metabolic disturbances. Management includes lifestyle modifications, dietary control, regular exercise, and appropriate medical treatment. Homoeopathy offers an individualized and holistic approach aimed at improving overall health and metabolic balance. Recent controlled and prospective operational trials have initiated a critical validation path for homoeopathy. Nevertheless, larger-scale multi-centric randomized trial configurations remain vital to definitively establish its objective therapeutic integration into global cardiovascular medical platforms.

REFERENCES

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran pathologic basis of disease. 10th ed. Philadelphia: Elsevier; 2021.
2. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 6th ed. New York: Garland Science; 2015.
3. World Health Organization. International statistical classification of diseases and related health problems: ICD-10. Geneva: World Health Organization; 2016.
4. Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. Indian J Endocrinol Metab. 2014;18[6]:708-15.
5. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38[32]:2459-72.
6. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370[9601]:1781-90.
7. Hahnemann S. Organon of medicine. 6th ed. New Delhi: B. Jain Publishers; 2002.
8. Kent JT. Lectures on homoeopathic philosophy. New Delhi: B. Jain Publishers; 2008.
9. Sharma B, Singh V, Manchanda RK. Homoeopathy in metabolic syndrome and dyslipidemia: an evaluative review. Indian J Res Homoeopathy. 2020;14[1]:56-63.
10. Close S. The genius of homoeopathy. New Delhi: B. Jain Publishers; 2003.
11. Schroyens F. Synthesis repertory: Repertorium Homoeopathicum Syntheticum. Version 9.1. London: Homoeopathic Book Publishers; 2004.
12. Nayak C, Singh V, Singh K, et al. A review of individual-

ized homoeopathic treatment in metabolic disorders. Indian J Res Homoeopathy. 2013;7[3]:116-22.
13. Rastogi DP. Evidence-based research in homoeopathy. New Delhi: Central Council for Research in Homoeopathy; 2008.
14. Banerjee A, Chakraborty PS. Homoeopathy in metabolic and lifestyle disorders: need for evidence-based validation. Indian J Res Homoeopathy. 2019;13 [3]:155-62.
15. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program [NCEP] expert panel on detection, evaluation, and treatment of high blood cholesterol in adults [Adult Treatment Panel III] final report. Circulation. 2002;106[25]:3143-421.
16. Libby P. Inflammation in atherosclerosis. Nature. 2002;420[6917]:868-74.
17. Pappan N, Awosika AO, Rehman A. Dyslipidemia. In: StatPearls. Treasure Island [FL]: StatPearls Publishing; 2024.
18. Mohamed-Yassin MS, Baharudin N, Abdul-Razak S, et al. Global prevalence of dyslipidemia: a protocol for a systematic review and meta-analysis. BMJ Open. 2021;11:e049662.
19. Xia Q, Chen Y, Yu Z, et al. Dyslipidemia in Chinese adults: prevalence, awareness, treatment, and control. Front Cardiovasc Med. 2023;10:1186330.
20. Zhang T, Chen J, Tang X, et al. HDL-adipocyte interaction in dyslipidemia. Lipids Health Dis. 2019;18:223.
21. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129[Suppl 2]:S1-S45.
22. Murphy R. Homoeopathic medical repertory. 1st ed. New Delhi: Indian Books & Periodical Syndicate; 1994.
23. Boericke W. Boericke's new manual of homoeopathic materia medica with repertory. 3rd ed. New Delhi: B. Jain Publishers; 2000.
24. Zandvoort RV. Complete repertory. Version 4.5. Tervuren, Belgium: RADAR Software.
25. Boger CM. Boger Boenninghausen's characteristics and repertory with corrected abbreviations and word index. 51st impr. New Delhi: B. Jain Publishers [P] Ltd.; 2021.
26. Clarke JH. A dictionary of practical materia medica. Vol. 1. Reprint ed. New Delhi: B. Jain Publishers; 1996.
27. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill; 2008.
28. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18[Suppl 1]:1-78.
29. Ray NP, Uchat U, Purkait R. An open-label randomized pilot trial to study the effectiveness of Allium sativum mother tincture [Ø] in comparison with individualized homoeopathic medicines in the treatment of dyslipidemia. Natl Homoeo Rec. 2019.
30. Husain A, Indani A, Bhutada P. Hypercholesterolemia effectively managed with homoeopathic medicine Gaultheria gaumeri [Yumel]: results from a clinical study in an academic clinical setup in North India. Int J Adv Med. 2017.
31. Govekar JP, Paul VK, Singh K, Oberai P, Roja V. Clinical evaluation of homoeopathic therapy in the management of hyperlipoproteinemia. Indian J Res Homoeopathy. 2008.
32. Varanasi R, Bhalerao R, Raveendar C, Kolli R, Sardala R, Prasad RVR, et al. Effect of individualised homoeopathic intervention in dyslipidaemia: an open-label, randomised, controlled, exploratory trial. Indian J Res Homoeopathy. 2025.
33. Naskar KK, Mishra O, Chattopadhyay A, et al. Efficacy of Dioscorea villosa 6CH in the treatment of dyslipidemia: a double-blind, randomized, placebo-controlled clinical trial. J Pharm Neg Results. 2020;11 [1]:59-64.
34. Raja M, Nayak C, Paital B, et al. Randomized trial on weight and lipid profile of obese patients treated with Garcinia cambogia. Med Sci. 2020;24[103].
35. Hu M, Zeng W, Tomlinson B. Evaluation of a Crataegus -based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evid Based Complement Alternat Med. 2014;2014:215731.
36. Kangjam A, Shinde SR. Evidence-based review of homoeopathic interventions for dyslipidemia in the Indian scenario. Int J Appl Res. 2025;11[4]:164-169.

How to cite this article: Pankaj Soni[1], Alpana Choudhary[2] Role of Homoeopathy in the Management of Dyslipidemia: A Comprehensive Review, Nat J. Med. Res. Yoga Sci., 2026; 3 (3) : 27-30

Source of Support: Nil, **Conflicts of Interest:** None declared.